Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open-Label, Phase 2 Study Evaluating Abemaciclib in Combination With Temozolomide Compared to Temozolomide Monotherapy in Children and Young Adults With Newly Diagnosed High-Grade Glioma Following Radiotherapy

NCT06413706 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT06413706
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06413706 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open-Label, Phase 2 Study Evaluating Abemaciclib in Combination With Temozolomide Compared to Temozolomide Monotherapy in Children and Young Adults With Newly Diagnosed High-Grade Glioma Following Radiotherapy
Lead sponsor
Eli Lilly and Company
Phase
Phase 2
Overall status
Active, not recruiting
Start date
October 25, 2024
Completion date
February 29, 2028
Enrollment
45 (estimated)
Sites
37

Conditions

As the registry lists them; a condition with its own page is linked.

glioma